Replimune (REPL) Return on Capital Employed (2018 - 2026)
Replimune (REPL) reported Return on Capital Employed of 116.44% for Q1 2026, down 6564.0% on a YoY basis from 1.8% in Q1 2025, and down 11.26% sequentially from 104.65% in Q4 2025.
Replimune (REPL) Return on Capital Employed (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Return on Capital Employed data on file, last reported at 116.44% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 6564.0% year-over-year to 116.44%; the trailing twelve-month figure through Mar 2026 stood at 116.44% (down 6564.0% YoY), and the FY2026 full-year result was 83.39%, down 2616.0% from the prior year.
- Return on Capital Employed fell to 116.44% in Q1 2026, from 104.65% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.15% in Q1 2022 to a low of 116.44% in Q1 2026.
- A 5-year average of 51.95% and a median of 47.92% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 83 bps in 2025 and slumped 6564 bps in 2026, its largest moves.
- Tracing REPL's Return on Capital Employed over 5 years: stood at 29.4% in 2022, then sank by 53 bps to 44.99% in 2023, then dropped by 7 bps to 47.92% in 2024, then tumbled by 118 bps to 104.65% in 2025, then declined by 11 bps to 116.44% in 2026.
- Business Quant data shows REPL's Return on Capital Employed at 116.44% in Q1 2026, 104.65% in Q4 2025, and 84.99% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -116.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -116.44% |
| Dec 31, 2025 | -104.65% |
| Sep 30, 2025 | -84.99% |
| Jun 30, 2025 | -65.36% |
| Mar 31, 2025 | -50.79% |
| Dec 31, 2024 | -47.92% |
| Sep 30, 2024 | -48.98% |
| Jun 30, 2024 | -49.72% |
| Mar 31, 2024 | -49.96% |
| Dec 31, 2023 | -44.99% |
| Sep 30, 2023 | -39.41% |
| Jun 30, 2023 | -32.35% |
| Mar 31, 2023 | -28.16% |
| Dec 31, 2022 | -29.40% |
| Sep 30, 2022 | -33.98% |
| Jun 30, 2022 | -29.96% |
| Mar 31, 2022 | -26.15% |
| Dec 31, 2021 | -22.79% |
| Sep 30, 2021 | -19.94% |
| Jun 30, 2021 | -17.27% |